Acute promyelocytic leukemia medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 49: | Line 49: | ||
***intercalation into [[DNA]]; [[inhibition]] of [[Type II topoisomerase|topoisomerase II]]. <ref name="McGowanChung2017">{{cite journal|last1=McGowan|first1=John V|last2=Chung|first2=Robin|last3=Maulik|first3=Angshuman|last4=Piotrowska|first4=Izabela|last5=Walker|first5=J Malcolm|last6=Yellon|first6=Derek M|title=Anthracycline Chemotherapy and Cardiotoxicity|journal=Cardiovascular Drugs and Therapy|volume=31|issue=1|year=2017|pages=63–75|issn=0920-3206|doi=10.1007/s10557-016-6711-0}}</ref> | ***intercalation into [[DNA]]; [[inhibition]] of [[Type II topoisomerase|topoisomerase II]]. <ref name="McGowanChung2017">{{cite journal|last1=McGowan|first1=John V|last2=Chung|first2=Robin|last3=Maulik|first3=Angshuman|last4=Piotrowska|first4=Izabela|last5=Walker|first5=J Malcolm|last6=Yellon|first6=Derek M|title=Anthracycline Chemotherapy and Cardiotoxicity|journal=Cardiovascular Drugs and Therapy|volume=31|issue=1|year=2017|pages=63–75|issn=0920-3206|doi=10.1007/s10557-016-6711-0}}</ref> | ||
***''Dosing'': | ***''Dosing'': | ||
****Idarubicin 12mg/m2 IV daily for 3 days, | ****Idarubicin 12mg/m2 IV daily for 3 days, daunorubicin 60 mg/m2 or 90 mfg/m2 IV daily for 3 days.<ref name="SunZhou2016">{{cite journal|last1=Sun|first1=Zimin|last2=Zhou|first2=Li|last3=Liu|first3=Xin|last4=Liu|first4=Huilan|last5=Zhu|first5=Weibo|last6=Cai|first6=Xiaoyan|last7=Song|first7=Kaidi|last8=Zheng|first8=Changcheng|last9=Tang|first9=Baolin|title=A comparative study of idarubicin 12 mg/m2 and 8 mg/m2 combined with cytarabine as the first induction regimen for adult acute myeloid leukemia patients|journal=OncoTargets and Therapy|year=2016|pages=985|issn=1178-6930|doi=10.2147/OTT.S96176}}</ref> | ||
***''Adverse effects'': | ***''Adverse effects'': | ||
****The most unique [[Adverse drug reaction|adverse]] effect is [[cardiomyopathy]].<ref name="VolkovaRussell2012">{{cite journal|last1=Volkova|first1=Maria|last2=Russell|first2=Raymond|title=Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment|journal=Current Cardiology Reviews|volume=7|issue=4|year=2012|pages=214–220|issn=1573403X|doi=10.2174/157340311799960645}}</ref> | ****The most unique [[Adverse drug reaction|adverse]] effect is [[cardiomyopathy]].<ref name="VolkovaRussell2012">{{cite journal|last1=Volkova|first1=Maria|last2=Russell|first2=Raymond|title=Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment|journal=Current Cardiology Reviews|volume=7|issue=4|year=2012|pages=214–220|issn=1573403X|doi=10.2174/157340311799960645}}</ref> | ||
Revision as of 14:46, 22 January 2019
|
Acute promyelocytic leukemia Microchapters |
|
Differentiating Acute promyelocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute promyelocytic leukemia medical therapy On the Web |
|
American Roentgen Ray Society Images of Acute promyelocytic leukemia medical therapy |
|
Directions to Hospitals Treating Acute promyelocytic leukemia |
|
Risk calculators and risk factors for Acute promyelocytic leukemia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2] Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [3]
Overview
The treatment of acute promyelocytic leukemia is broadly divided into anti-leukemia therapies and supportive therapies. Anti-leukemia therapies function to eliminate cancer cells, whereas supportive therapies are temporizing measures that can control the disease for a short time until anti-leukemic therapy takes effect. Anti-leukemic therapies include all-trans retinoic acid, arsenic trioxide, gemtuzumab ozogamicin, and cytarabine. Supportive therapies include transfusions (such as cryopreciptate or platelet transfusions) and granulocyte colony stimulating factor.
Medical Therapy
Anti-leukemic Therapies
- All-trans retinoic acid:
- Acute promyelocytic leukemia is unique among the leukemias distinguished by its sensitivity to all-trans retinoic acid, a derivative of vitamin A. Treatment with all-trans retinoic acid causes differentiation of the immature leukemic promyelocytes into mature granulocytes. This is typically combined with anthracycline-based chemotherapy resulting in a clinical remission in approximately 90% of patients. The introduction of all-trans retinoic acid has revolutionized the treatment paradigm and outcomes in acute promyelocytic leukemia. The 5-year mortality has decreased from 82% to 36% since the introduction of all-trans retinoic acid.[1]
- Mechanism of action:
- Dosing:
- 45mg/m2 PO daily (typically 22.5mg/m2 PO divided twice daily), given on days 1-14 of a 28-day cycle (2 weeks on, 2 weeks off), for a total of 7 cycles
- Adverse effects:
- The most unique adverse effect of all-trans retinoic acid is differentiation syndrome. This was formerly known as retinoic acid syndrome, until it was noted that arsenic trioxide could also result in a similar phenomenon. The etiology of differentiation syndrome has been attributed to capillary leak syndrome from cytokine release from the differentiating promyelocytes. Differentiation syndrome is characterized by the development of dyspnea, fever, weight gain, peripheral edema and is treated with dexamethasone.[2][3]
- Arsenic trioxide:
- Arsenic trioxide is commonly used in the treatment of acute promyelocytic leukemia in combination with all-trans retinoic acid.[4]
- Mechanism of action:
- Dosing:
- 0.15mg/kg IV daily for days 1-30 of a 60-day cycle (4 weeks on, 4 weeks off), for a total of 4 cycles.[5]
- Adverse effects:
- The adverse effects of arsenic trioxide include myelosuppression, QT interval prolongation, and liver dysfunction.[6]
- Liver dysfunction occurs in approximately one-third of patients.[7]
- Gemtuzumab ozogamycin:
- This is an anti-CD33 antibody conjugated to the anti-tumor antibiotic calicheamicin. Gemtuzumab ozogamycin is FDA-approved for the treatment of patients with newly diagnosed acute myeloid leukemia expressing the CD33 antigen.[8]
- Gemtuzumab ozogamycin shows efficacy in acute promyelocytic leukemia. This medication was originally approved in the year 2000 for relapsed acute myeloid leukemia, then was withdrawn from the marker a few years later, then re-introduced to the marker in 2017.[9]
- Mechanism of action:
- Dosing:
- 3 mg/m2 IV on days 1, 4, and 7 of the induction regimen.[11]
- Adverse effects:
- The most unique adverse effect is hepatic venoocclusive disease, which is due to the ozogamycin component.[12]
- Cytarabine:
- This is a cytotoxic chemotherapy that is used in high-risk acute promyelocytic leukemia along with all-trans retinoic acid.[13][14]
- Importantly, cytarabine is not required for the treatment of acute promyelocytic leukemia, as studies from the GIMEMA cooperative group in Italy and the PETHEMA cooperative group in Spain showed that the combination of anthracycline plus all-trans retinoic acid is equally as effective as a cytarabine-containing regimen.[15][16]
- Mechanism of action:
- Incorporation into DNA and disruption of DNA synthesis.[17]
- Dosing:
- 100 mg/m2 IV infusion continuously for 7 days.[18]
- Adverse effects:
- Common adverse effects include rash; myelosuppression (infections, fatigue, bleeding); cerebellar dysfunction; conjunctivitis.[19]
- Anthacyclines:
- These are cytotoxic chemotherapy agents that are used in high-risk acute promyelocytic leukemia along with all-trans retinoic acid.[13][14]
- Mechanism of action:
- intercalation into DNA; inhibition of topoisomerase II. [20]
- Dosing:
- Idarubicin 12mg/m2 IV daily for 3 days, daunorubicin 60 mg/m2 or 90 mfg/m2 IV daily for 3 days.[21]
- Adverse effects:
- The most unique adverse effect is cardiomyopathy.[22]
- This can include arrhythmias in the acute setting and heart failure in the long-term setting. Patients who are at highest risk for cardiomyopathy from anthracyclines include those with pre-existing heart disease, diabetes, hypertension, and elderly patients.[23]
- Mucositis is also a common adverse effect.[24]
- These are cytotoxic chemotherapy agents that are used in high-risk acute promyelocytic leukemia along with all-trans retinoic acid.[13][14]
Supportive Therapies
- Cryoprecipitate transfusion:
- Cryoprecipitate is commonly given to patients with acute promyelocytic leukemia who have disseminated intravascular coagulation. Low fibrinogen levels (less than 100 mg/dl) warrant transfusion of cryoprecipitate. Cryoprecipitate contains factor I, factor VIII, and von Willebrand factor.[25]
- Adverse effects:
- Risks of cryoprecipitate transfusion include volume overload (low risk) and transfusion reaction. In rare cases, sepsis can occur from contaminated product.[26]
- Packed red blood cell transfusion:
- Red blood cell transfusion is commonly done in patients with acute promyelocytic leukemia. Transfusion is indicated when the hemoglobin level decreases below 7 g/dl.
- Adverse effects:
- Risks of red blood cell transfusion include volume overload, alloimmunization, iron overload, and infection (if the product is contaminated). Alloimmunization is usually prevents with clerical checks and proper blood banking techniques. Iron overload occurs after many repeated transfusion and can be prevented via the use of iron chelators such as deferiprone, deferasirox, and deferoxamine.
- Platelet transfusion:
- Platelet transfusion is indicated when the platelet count decreases to less than 10,000 cells per microliter. This low platelet count occurs especially when a patient received induction chemotherapy, such as cytarabine or anthacycline.
- Adverse effects:
- Risks include sepsis (since platelet units are stored at room temperature and there is a high risk for contamination), volume overload, and thrombosis (less likely).
- Granulocyte colony stimulating factor (G-CSF):
- G-CSF is sometimes uses to help improve the neutrophil count in patients with acute promyelocytic leukemia. It is important to use G-CSF only when there is no active leukemia, as G-CSF can stimulate the proliferation of leukemic blasts. Patients who receive G-CSF are usually those who have had a favorable anti-tumor response to chemotherapy but have not recovered their normal blood counts. G-CSF helps enhance normal blood cell count recovery.
- Adverse effects:
- The most common adverse effects are bone pain, leukocytosis, and injection site erythema and pain. Bone pain can be alleviated via loratadine or other histamine receptor blockers.
References
- ↑ Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E; et al. (2017). "Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab". Blood. 129 (10): 1275–1283. doi:10.1182/blood-2016-09-736686. PMC 5413297. PMID 28003274.
- ↑ Montesinos, Pau; Sanz, Miguel A (2011). "THE DIFFERENTIATION SYNDROME IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA: EXPERIENCE OF THE PETHEMA GROUP AND REVIEW OF THE LITERATURE". Mediterranean Journal of Hematology and Infectious Diseases. 3 (1): e2011059. doi:10.4084/mjhid.2011.059. ISSN 2035-3006.
- ↑ Montesinos, P.; Bergua, J. M.; Vellenga, E.; Rayon, C.; Parody, R.; de la Serna, J.; Leon, A.; Esteve, J.; Milone, G.; Deben, G.; Rivas, C.; Gonzalez, M.; Tormo, M.; Diaz-Mediavilla, J.; Gonzalez, J. D.; Negri, S.; Amutio, E.; Brunet, S.; Lowenberg, B.; Sanz, M. A. (2008). "Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors". Blood. 113 (4): 775–783. doi:10.1182/blood-2008-07-168617. ISSN 0006-4971.
- ↑ 4.0 4.1 Kumar S, Yedjou CG, Tchounwou PB (2014). "Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells". J Exp Clin Cancer Res. 33: 42. doi:10.1186/1756-9966-33-42. PMC 4049373. PMID 24887205.
- ↑ Iland, Harry J.; Seymour, John F. (2013). "Role of Arsenic Trioxide in Acute Promyelocytic Leukemia". Current Treatment Options in Oncology. 14 (2): 170–184. doi:10.1007/s11864-012-0223-3. ISSN 1527-2729.
- ↑ McCulloch D, Brown C, Iland H (2017). "Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives". Onco Targets Ther. 10: 1585–1601. doi:10.2147/OTT.S100513. PMC 5359123. PMID 28352191.
- ↑ Falchi L, Verstovsek S, Ravandi-Kashani F, Kantarjian HM (2016). "The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy". Cancer. 122 (8): 1160–8. doi:10.1002/cncr.29852. PMC 5042140. PMID 26716387.
- ↑ Jen, Emily Y.; Ko, Chia-Wen; Lee, Jee Eun; Del Valle, Pedro L.; Aydanian, Antonina; Jewell, Charles; Norsworthy, Kelly J.; Przepiorka, Donna; Nie, Lei; Liu, Jiang; Sheth, Christopher M.; Shapiro, Marjorie; Farrell, Ann T.; Pazdur, Richard (2018). "FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia". Clinical Cancer Research. 24 (14): 3242–3246. doi:10.1158/1078-0432.CCR-17-3179. ISSN 1078-0432.
- ↑ Wei, Andrew H.; Tiong, Ing S. (2017). "Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML". Blood. 130 (23): 2469–2474. doi:10.1182/blood-2017-08-784066. ISSN 0006-4971.
- ↑ Planque, Robert; Jager, Eva; van der Velden, Vincent H. J.; te Marvelde, Jeroen G.; Walter, Roland B.; Agur, Zvia; Vainstein, Vladimir (2011). "Targeted Drug Delivery by Gemtuzumab Ozogamicin: Mechanism-Based Mathematical Model for Treatment Strategy Improvement and Therapy Individualization". PLoS ONE. 6 (9): e24265. doi:10.1371/journal.pone.0024265. ISSN 1932-6203.
- ↑ Lo Coco F, Ammatuna E, Noguera N (January 2006). "Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin". Clin Adv Hematol Oncol. 4 (1): 57–62, 76–7. PMID 16562371.
- ↑ Baron, Jeffrey; Wang, Eunice S. (2018). "Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia". Expert Review of Clinical Pharmacology. 11 (6): 549–559. doi:10.1080/17512433.2018.1478725. ISSN 1751-2433.
- ↑ 13.0 13.1 Ravandi, Farhad; Estey, Eli; Jones, Dan; Faderl, Stefan; O'Brien, Susan; Fiorentino, Jackie; Pierce, Sherry; Blamble, Deborah; Estrov, Zeev; Wierda, William; Ferrajoli, Alessandra; Verstovsek, Srdan; Garcia-Manero, Guillermo; Cortes, Jorge; Kantarjian, Hagop (2009). "Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin". Journal of Clinical Oncology. 27 (4): 504–510. doi:10.1200/JCO.2008.18.6130. ISSN 0732-183X.
- ↑ 14.0 14.1 Zhang, Li; Zou, Yao; Chen, Yumei; Guo, Ye; Yang, Wenyu; Chen, Xiaojuan; Wang, Shuchun; Liu, Xiaoming; Ruan, Min; Zhang, Jiayuan; Liu, Tianfeng; Liu, Fang; Qi, Benquan; An, Wenbin; Ren, Yuanyuan; Chang, Lixian; Zhu, Xiaofan (2018). "Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial". BMC Cancer. 18 (1). doi:10.1186/s12885-018-4280-2. ISSN 1471-2407.
- ↑ Lo-Coco, F.; Avvisati, G.; Vignetti, M.; Breccia, M.; Gallo, E.; Rambaldi, A.; Paoloni, F.; Fioritoni, G.; Ferrara, F.; Specchia, G.; Cimino, G.; Diverio, D.; Borlenghi, E.; Martinelli, G.; Di Raimondo, F.; Di Bona, E.; Fazi, P.; Peta, A.; Bosi, A.; Carella, A. M.; Fabbiano, F.; Pogliani, E. M.; Petti, M. C.; Amadori, S.; Mandelli, F. (2010). "Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group". Blood. 116 (17): 3171–3179. doi:10.1182/blood-2010-03-276196. ISSN 0006-4971.
- ↑ Ortega, Juan J.; Madero, Luis; Martín, Guillermo; Verdeguer, Amparo; García, Purificación; Parody, Ricardo; Fuster, José; Molines, Antonio; Novo, Andrés; Debén, Guillermo; Rodríguez, Antonia; Conde, Eulogio; de la Serna, Javier; Allegue, María J.; Capote, Francisco J.; González, José D.; Bolufer, Pascual; González, Marcos; Sanz, Miguel A. (2005). "Treatment With All-TransRetinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group". Journal of Clinical Oncology. 23 (30): 7632–7640. doi:10.1200/JCO.2005.01.3359. ISSN 0732-183X.
- ↑ Prakasha Gowda, A. S.; Polizzi, Joanna M.; Eckert, Kristin A.; Spratt, Thomas E. (2010). "Incorporation of Gemcitabine and Cytarabine into DNA by DNA Polymerase β and Ligase III/XRCC1". Biochemistry. 49 (23): 4833–4840. doi:10.1021/bi100200c. ISSN 0006-2960.
- ↑ Löwenberg, Bob; Pabst, Thomas; Vellenga, Edo; van Putten, Wim; Schouten, Harry C.; Graux, Carlos; Ferrant, Augustin; Sonneveld, Pieter; Biemond, Bart J.; Gratwohl, Alois; de Greef, Georgine E.; Verdonck, Leo F.; Schaafsma, Martijn R.; Gregor, Michael; Theobald, Matthias; Schanz, Urs; Maertens, Johan; Ossenkoppele, Gert J. (2011). "Cytarabine Dose for Acute Myeloid Leukemia". New England Journal of Medicine. 364 (11): 1027–1036. doi:10.1056/NEJMoa1010222. ISSN 0028-4793.
- ↑ Shepshelovich, Daniel; Edel, Yonatan; Goldvaser, Hadar; Dujovny, Tal; Wolach, Ofir; Raanani, Pia (2015). "Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study". British Journal of Clinical Pharmacology. 79 (4): 685–691. doi:10.1111/bcp.12530. ISSN 0306-5251.
- ↑ McGowan, John V; Chung, Robin; Maulik, Angshuman; Piotrowska, Izabela; Walker, J Malcolm; Yellon, Derek M (2017). "Anthracycline Chemotherapy and Cardiotoxicity". Cardiovascular Drugs and Therapy. 31 (1): 63–75. doi:10.1007/s10557-016-6711-0. ISSN 0920-3206.
- ↑ Sun, Zimin; Zhou, Li; Liu, Xin; Liu, Huilan; Zhu, Weibo; Cai, Xiaoyan; Song, Kaidi; Zheng, Changcheng; Tang, Baolin (2016). "A comparative study of idarubicin 12 mg/m2 and 8 mg/m2 combined with cytarabine as the first induction regimen for adult acute myeloid leukemia patients". OncoTargets and Therapy: 985. doi:10.2147/OTT.S96176. ISSN 1178-6930.
- ↑ Volkova, Maria; Russell, Raymond (2012). "Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment". Current Cardiology Reviews. 7 (4): 214–220. doi:10.2174/157340311799960645. ISSN 1573-403X.
- ↑ Herrmann, Joerg; Lerman, Amir; Sandhu, Nicole P.; Villarraga, Hector R.; Mulvagh, Sharon L.; Kohli, Manish (2014). "Evaluation and Management of Patients With Heart Disease and Cancer: Cardio-Oncology". Mayo Clinic Proceedings. 89 (9): 1287–1306. doi:10.1016/j.mayocp.2014.05.013. ISSN 0025-6196.
- ↑ Fathi AT, Karp JE (September 2009). "New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines". Curr Oncol Rep. 11 (5): 346–52. PMC 3066101. PMID 19679009.
- ↑ Nascimento B, Goodnough LT, Levy JH (December 2014). "Cryoprecipitate therapy". Br J Anaesth. 113 (6): 922–34. doi:10.1093/bja/aeu158. PMC 4627369. PMID 24972790.
- ↑ Pandey S, Vyas GN (May 2012). "Adverse effects of plasma transfusion". Transfusion. 52 Suppl 1: 65S–79S. doi:10.1111/j.1537-2995.2012.03663.x. PMC 3356109. PMID 22578374.